AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash
pharmaphorum
SEPTEMBER 29, 2021
Qulipta (atogepant) is AbbVie’s second oral CGRP inhibitor after Ubrelvy (ubrogepant) – which was approved for the acute treatment of migraine attacks in 2019 – and rounds out a range that also includes the injectable Botox. Botox is prescribed for the prevention of headaches in adults diagnosed with chronic migraine.
Let's personalize your content